AstraZeneca vet heads to UK biotech as the new CSO; Mallinckrodt touts positive PhIII data
→ UK-based early cancer detection company Oncimmune Holdings has welcomed Tariq Sethi as CSO, Matthew Luttrell as CMO and Cléa Rosenfeld as head of investor relations. Sethi is a professor of respiratory medicine at King’s College London. Before jumping on board at Oncimmune, Sethi was chief physician-scientist, vice president in the clinical discovery unit at AstraZeneca. He is also the founder of Galecto Biotech. Luttrell joins the company after a stint as head of hematology, growth and emerging markets at Shire (now Takeda). He’s served in other roles at Eli Lilly, Novo Nordisk, Gilead, and GSK. Rosenfeld brings experience to her new role from her time as head of investor relations at Shire, where she helped bring the company from a FTSE 250 Company to a top 50 FTSE company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.